@article{3032311,
    title = "miRNA-seq and clinical evaluation in multiple myeloma: miR-181a
overexpression predicts short-term disease progression and poor
post-treatment outcome",
    author = "Papadimitriou, Maria-Alexandra and Papanota, Aristea-Maria and and Adamopoulos, Panagiotis G. and Pilala, Katerina-Marina and Liacos, and Christine-Ivy and Malandrakis, Panagiotis and Mavrianou-Koutsoukou, and Nefeli and Patseas, Dimitrios and Eleutherakis-Papaiakovou, Evangelos and and Gavriatopoulou, Maria and Kastritis, Efstathios and Avgeris, and Margaritis and Dimopoulos, Meletios-Athanasios and Terpos, Evangelos and and Scorilas, Andreas",
    journal = "British Journal of Cancer",
    year = "2022",
    volume = "126",
    number = "1",
    pages = "79-90",
    publisher = "SPRINGERNATURE",
    issn = "0007-0920, 1532-1827",
    doi = "10.1038/s41416-021-01602-8",
    abstract = "Background Despite significant advances in multiple myeloma (MM)
therapy, disease relapse and treatment resistance remain major obstacles
in clinical management. Herein, we have studied the clinical utility of
miRNAs in improving patients' risk-stratification and prognosis. Methods
miRNA-seq was performed in CD138+ plasma cells of MM, smoldering
multiple myeloma (sMM) and monoclonal gammopathy of undetermined
significance (MGUS) patients. The screening MM cohort consisted of 138
patients. miRNA levels of CD138+ plasma cells were quantified by RT-qPCR
following 3 `-end RNA polyadenylation. Disease progression and patients'
death were used as clinical end-point events. Internal validation was
conducted by bootstrap analysis. Clinical net benefit on disease
prognosis was assessed by decision curve analysis. Kruykov et al. 2016
served as validation cohort (n = 151). Results miRNA-seq highlighted
miR-181a to be upregulated in MM vs. sMM/MGUS, and R-ISS III vs. I
patients. Screening and validation cohorts confirmed the significantly
higher risk for short-term progression and worse survival of the
patients overexpressing miR-181a. Multivariate models integrating
miR-181a with disease established markers led to superior
risk-stratification and clinical benefit for MM prognosis. Conclusions
CD138+ overexpression of miR-181a was strongly correlated with inferior
disease outcome and contributed to superior prediction of MM patients
early progression, supporting personalised prognosis and treatment
decisions."
}